Hannah C Kulka1, Andreas Zeller, Jürgen Fornaro, Walter A Wuillemin, Stavros Konstantinides, Michael Christ. 1. Institute for Anesthesiology, Universiy Hospital Essen; Canton Hospital Basel-Land, University of Basel, Switzerland; Radiology, Canton Hospital Lucerne, Switzerland; Hematology, Canton Hospital Lucerne, Switzerland; School of Medicine, University of Mainz Emergency Center,; Canton Hospital Lucerne, Switzerland.
Abstract
BACKGROUND: Physicians from many different specialties see patients suffering from acute pulmonary embolism (PE), which has an incidence of 39-115 cases per 100 000 persons per year. Because PE can be life-threatening, a rapid, targeted response is essential. METHODS: This review is based on pertinent publications retrieved by a selective literature search of international databases, with particular attention to current guidelines and expert opinions. RESULTS: Whenever PE is suspected, clinical assessment tools must be applied for risk stratification and diagnostic evaluation. The PERC (Pulmonary Embolism Rule-out Criteria) and the YEARS algorithm lead to more effective diagnosis. For hemodynamically unstable patients, bedside echocardiography is of high value and enables risk stratification. New oral anticoagulants have fewer hemorrhagic complications than vitamin K antagonists and are not inferior to them with respect to the risk of recurrent PE (hazard ratio 0.84-1.09). The duration of anticoagulation is set according to the risk of recurrence. Systemic thrombolysis is recommended for patients with a high-risk PE, in whom it significantly reduces mortality (odds ratio 0.53, number needed to treat 59). Surgical or interventional techniques can be considered if thrombolysis is contraindicated or unsuccessful. CONCLUSION: Newly introduced diagnostic aids and algorithms simplify the diagnosis and treatment of acute PE while continuing to assure a high degree of patient safety.
BACKGROUND: Physicians from many different specialties see patients suffering from acute pulmonary embolism (PE), which has an incidence of 39-115 cases per 100 000 persons per year. Because PE can be life-threatening, a rapid, targeted response is essential. METHODS: This review is based on pertinent publications retrieved by a selective literature search of international databases, with particular attention to current guidelines and expert opinions. RESULTS: Whenever PE is suspected, clinical assessment tools must be applied for risk stratification and diagnostic evaluation. The PERC (Pulmonary Embolism Rule-out Criteria) and the YEARS algorithm lead to more effective diagnosis. For hemodynamically unstable patients, bedside echocardiography is of high value and enables risk stratification. New oral anticoagulants have fewer hemorrhagic complications than vitamin K antagonists and are not inferior to them with respect to the risk of recurrent PE (hazard ratio 0.84-1.09). The duration of anticoagulation is set according to the risk of recurrence. Systemic thrombolysis is recommended for patients with a high-risk PE, in whom it significantly reduces mortality (odds ratio 0.53, number needed to treat 59). Surgical or interventional techniques can be considered if thrombolysis is contraindicated or unsuccessful. CONCLUSION: Newly introduced diagnostic aids and algorithms simplify the diagnosis and treatment of acute PE while continuing to assure a high degree of patient safety.
Authors: Mary A M Rogers; Deborah A Levine; Neil Blumberg; Scott A Flanders; Vineet Chopra; Kenneth M Langa Journal: Circulation Date: 2012-04-03 Impact factor: 29.690
Authors: Martin Mockel; Julia Searle; Reinhold Muller; Anna Slagman; Harald Storchmann; Philipp Oestereich; Werner Wyrwich; Angela Ale-Abaei; Joern O Vollert; Matthias Koch; Rajan Somasundaram Journal: Eur J Emerg Med Date: 2013-04 Impact factor: 2.799
Authors: W Zondag; I C M Mos; D Creemers-Schild; A D M Hoogerbrugge; O M Dekkers; J Dolsma; M Eijsvogel; L M Faber; H M A Hofstee; M M C Hovens; G J P M Jonkers; K W van Kralingen; M J H A Kruip; T Vlasveld; M J M de Vreede; M V Huisman Journal: J Thromb Haemost Date: 2011-08 Impact factor: 5.824
Authors: Guy Meyer; Eric Vicaut; Thierry Danays; Giancarlo Agnelli; Cecilia Becattini; Jan Beyer-Westendorf; Erich Bluhmki; Helene Bouvaist; Benjamin Brenner; Francis Couturaud; Claudia Dellas; Klaus Empen; Ana Franca; Nazzareno Galiè; Annette Geibel; Samuel Z Goldhaber; David Jimenez; Matija Kozak; Christian Kupatt; Nils Kucher; Irene M Lang; Mareike Lankeit; Nicolas Meneveau; Gerard Pacouret; Massimiliano Palazzini; Antoniu Petris; Piotr Pruszczyk; Matteo Rugolotto; Aldo Salvi; Sebastian Schellong; Mustapha Sebbane; Bozena Sobkowicz; Branislav S Stefanovic; Holger Thiele; Adam Torbicki; Franck Verschuren; Stavros V Konstantinides Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: Carlos R Martinez Licha; Chelsea M McCurdy; Sarina Masso Maldonado; Lawrence S Lee Journal: Ann Thorac Cardiovasc Surg Date: 2019-10-05 Impact factor: 1.520